Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ryuki Kitamoto"'
Autor:
Motohiro Itotani, Makoto Matsumoto, Izuru Nakamura, Ohba Yoshio, Toshio Shinohara, Yohei Hayashi, Norimitsu Hariguchi, Shunpei Ishikawa, Miki Matsuba, Yoshikazu Kawano, Yoshikazu Haraguchi, Yukitaka Uematsu, Xiuhao Chen, Mamoru Fujiwara, Ryuki Kitamoto, Hiroshi Shimizu, Isao Takemura
Publikováno v:
Antimicrobial Agents and Chemotherapy
There is an urgent need for new, potent antituberculosis (anti-TB) drugs with novel mechanisms of action that can be included in new regimens to shorten the treatment period for TB. After screening a library of carbostyrils, we optimized 3,4-dihydroc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40caed769eea3a26ef9d04c0b3a96237
https://doi.org/10.1128/aac.02020-19
https://doi.org/10.1128/aac.02020-19
Autor:
Akihito Nishiyama, Makoto Matsumoto, Tohru Abe, Sohkichi Matsumoto, Kimiko Itoh, Yoshitaka Tateishi, Shaban A. Kaboso, Tsutomu Sato, Ryuki Kitamoto, Xiuhao Chen, Kentaro Kaneko, Yusuke Inoue, Mikayo Hayashi, Mayuko Osada-Oka, Yoshikazu Kawano, Mamoru Fujiwara, Yukiko Nishiuchi, Masanori Kawasaki
Publikováno v:
Antimicrob Agents Chemother
Delamanid (DLM), a nitro-dihydroimidazooxazole derivative currently approved for pulmonary multidrug-resistant tuberculosis (TB) therapy, is a prodrug activated by mycobacterial 7,8-didemethyl-8-hydroxy 5-deazaflavin electron transfer coenzyme (F(420
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e37364cfd6ccad045c35200f11fab65
https://pubmed.ncbi.nlm.nih.gov/32152081
https://pubmed.ncbi.nlm.nih.gov/32152081
Autor:
Tatsuo Tomishige, Izuru Nakamura, Miki Matsuba, Mamoru Fujiwara, Hiroyuki Hashizume, Ryuki Kitamoto, Erina Hanaki, Xiuhao Chen, Makoto Matsumoto, Ohba Yoshio
Publikováno v:
Antimicrobial Agents and Chemotherapy. 61
Tuberculosis (TB) treatment is long and requires multiple drugs, likely due to various phenotypes of TB bacilli with variable drug susceptibilities. Drugs with broad activity are urgently needed. This study aimed to evaluate delamanid's activity agai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91d116a67b055b3b2f6599eed429dbcf
https://doi.org/10.1128/aac.02402-16
https://doi.org/10.1128/aac.02402-16
Autor:
Xiuhao, Chen, Hiroyuki, Hashizume, Tatsuo, Tomishige, Izuru, Nakamura, Miki, Matsuba, Mamoru, Fujiwara, Ryuki, Kitamoto, Erina, Hanaki, Yoshio, Ohba, Makoto, Matsumoto
Publikováno v:
Antimicrobial agents and chemotherapy. 61(6)
Tuberculosis (TB) treatment is long and requires multiple drugs, likely due to various phenotypes of TB bacilli with variable drug susceptibilities. Drugs with broad activity are urgently needed. This study aimed to evaluate delamanid's activity agai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4ee2035647218669fc7f05fafae068c2
https://pubmed.ncbi.nlm.nih.gov/28373190
https://pubmed.ncbi.nlm.nih.gov/28373190